Stock Analiz

Sight Sciences, Inc. SGHT

Medical/Dental Instruments · IPO 2021 · data as of November 13, 2026

$10.83Market cap $602M
Open the interactive analysis →

Sight Sciences, Inc. (SGHT) is a healthcare company listed in the US with a market value of about $602M. In the twelve months to September 30, 2026 it had revenue of $88M and net income of -$28M, a net margin of -32.1%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 23% a year, a 5-year average ROIC of -28%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 97% below the current price.

About Sight Sciences

Sight Sciences is listed in the US and classified in medical/dental instruments, IPO year 2021. Revenue went from $28M in 2020 to $77M in 2025, growth of about 22.9% a year. It was profitable in 0 of the last 6 years in our data. Its share count rose by 9% over three years (dilution for shareholders). It spends 19% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth2/5
Track record1/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S6.8
P/B12.2
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-2.8%
Shareholder yield0.0%
Intrinsic value vs. price−97%

Growth and quality

Revenue growth (1 yr)-3.1%
Revenue growth (5 yrs, per year)22.9%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-86.4%
ROIC (5-yr avg.)-27.5%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 6 years

Fiscal yearTTM202520242023202220212020
Revenue$88M$77M$80M$81M$71M$49M$28M
Net income-$28M-$38M-$52M-$56M-$86M-$63M-$35M
Free cash flow-$17M-$30M-$23M-$48M-$77M-$53M-$33M
EPS (diluted)$-0.52$-0.74$-1.03$-1.14$-1.80$-2.36$-3.71
Net margin-32.1%-49.7%-64.5%-68.5%-120.9%-128.6%-125.5%
ROIC—-28.0%-31.2%-29.1%-34.0%-15.3%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 6 analysts is $12.25, 13% above the current price; targets range from $10.00 to $14.00; the consensus rating is “Buy”; expected EPS is $-0.46 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Sight Sciences stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 97% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Sight Sciences pay a dividend?

Not currently.

Is Sight Sciences a good stock to buy?

We do not give buy or sell advice. Sight Sciences scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.